ProPharma Group Revenue and Competitors

Location

$8.6M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ProPharma Group's estimated annual revenue is currently $684.4M per year.(i)
  • ProPharma Group's estimated revenue per employee is $321,600
  • ProPharma Group's total funding is $8.6M.

Employee Data

  • ProPharma Group has 2128 Employees.(i)
  • ProPharma Group grew their employee count by -4% last year.

ProPharma Group's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
Sr. VP, Global Clinical OperationsReveal Email/Phone
3
CEOReveal Email/Phone
4
VPReveal Email/Phone
5
VPReveal Email/Phone
6
Pharmacovigilance Officer IReveal Email/Phone
7
VP, Biostatistics and ProgrammingReveal Email/Phone
8
EVP, Global Business Development & OperationsReveal Email/Phone
9
VP, Compliance and Quality AssuranceReveal Email/Phone
10
VP, Business Development Regulatory SciencesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.3M519%N/AN/A
#2
$24.7M123-6%N/AN/A
#3
$5.6M28-10%N/AN/A
#4
$26.7M133-4%N/AN/A
#5
$4.4M22-19%N/AN/A
#6
$74.6M3719%N/AN/A
#7
$22.7M1133%N/AN/A
#8
$12.3M858%$20MN/A
#9
$3.8M196%N/AN/A
#10
$5.6M2812%N/AN/A
Add Company

What Is ProPharma Group?

Xendo, Sofus Regulatory Affairs, and SOLUTIONS in Health are now ProPharma Group. Visit our website to learn more. ProPharma Group is an industry leader providing life science consulting, medical information, pharmacovigilance, and regulatory affairs services to the pharmaceutical, biotechnology, and medical device industries. We enable clients to deliver their products to patients in the most safe, compliant, and timely manner possible. Backed by years of experience, our highly trained team understands the needs companies have in this heavily regulated environment. ProPharma Group's experts custom tailor solutions for each of our clients based upon their unique needs and goals. By creating an integrated compliance solution, ProPharma Group is your global, single source for the insights and services needed to maintain the highest level of value and patient safety throughout the product lifecycle. We are headquartered in Overland Park, Kansas with offices across the country, and around the world.

keywords:N/A

$8.6M

Total Funding

2128

Number of Employees

$684.4M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ProPharma Group News

2022-03-30 - Global Clinical Trials Market Research Report to 2026 ...

ProPharma Group Holdings, LLC 13.12. SGS S.A. 13.13. SIRO Clinpharm Private Limited 13.14. Syneos Health, Inc.

2022-03-22 - Odyssey-backed PPG buys M Squared Associates

ProPharma Group is the global, independent, single-source provider of regulatory, clinical and compliance services serving pharmaceutical,...

2021-10-06 - ProPharma Group Announces the Acquisition of Pharmica Consulting

“This is a powerful combination of two highly complementary businesses,” said Michael Stomberg, CEO of ProPharma Group. “We are confident this acquisition will come as a value-added partnership to our combined client base." OVERLAND PARK, Kan. (PRWEB) October 06, 2021 ProPharma Group, a portfo ...

2021-09-02 - ProPharma Group and The Planet Group Announce Executive Leadership Changes and Branding of Combined Company

“We look forward to the next phase of growth as we continue on our mission and higher purpose to improve patient health and safety, said Michael Stomberg, ProPharma Group’s CEO. OVERLAND PARK, Kan. (PRWEB) September 02, 2021 ProPharma Group, a portfolio company of Odyssey Investment Partners, ...

2021-08-10 - ProPharma Group Announces the Acquisition of iSafety Systems

“This acquisition continues to strengthen ProPharma Group’s position as the leading global provider of regulatory and compliance consulting, clinical research, pharmacovigilance, and medical information services," said Dawn Sherman, ProPharma Group's CEO. OVERLAND PARK, Kan. (PRWEB) August 10, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$537.3M31986%N/A
#2
$1120.4M4446N/AN/A
#3
N/A44029-1%$5.4M